Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1259897

Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group


Janez, Andrej; Muzurovic, Emir; Stoian, Anca Pantea; Haluzik, Martin; Guja, Cristian; Czupryniak, Leszek; Duvnjak, Lea; Lalic, Nebojsa; Tankova, Tsvetalina; Bogdanski, Pawel et al.
Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group // International journal of cardiology, 365 (2022), 8-18 doi:10.1016/j.ijcard.2022.07.017 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1259897 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group

Autori
Janez, Andrej ; Muzurovic, Emir ; Stoian, Anca Pantea ; Haluzik, Martin ; Guja, Cristian ; Czupryniak, Leszek ; Duvnjak, Lea ; Lalic, Nebojsa ; Tankova, Tsvetalina ; Bogdanski, Pawel ; Papanas, Nikolaos ; Nunes, Josè Silva ; Kempler, Peter ; Fras, Zlatko ; Rizzo, Manfredi

Izvornik
International journal of cardiology (0167-5273) 365 (2022); 8-18

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Algorithm ; Cardiovascular outcomes trials ; GLP-1 receptor agonists ; Treatment ; Type 2 diabetes mellitus.

Sažetak
Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have occurred. This document from a Eastern and Southern European Diabetes Expert Group discusses the results of GLP-1 RA CV outcomes trials, their impact on recent clinical guidelines for the management of T2DM, and some selected combination regimens utilising GLP-1 RAs. We also propose an algorithm for guiding GLP-1 RA-based treatment according to patients' characteristics, which can be easily applied in every day clinical practice.

Izvorni jezik
Engleski



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Zagreb

Profili:

Avatar Url Lea Smirčić-Duvnjak (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Janez, Andrej; Muzurovic, Emir; Stoian, Anca Pantea; Haluzik, Martin; Guja, Cristian; Czupryniak, Leszek; Duvnjak, Lea; Lalic, Nebojsa; Tankova, Tsvetalina; Bogdanski, Pawel et al.
Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group // International journal of cardiology, 365 (2022), 8-18 doi:10.1016/j.ijcard.2022.07.017 (međunarodna recenzija, članak, znanstveni)
Janez, A., Muzurovic, E., Stoian, A., Haluzik, M., Guja, C., Czupryniak, L., Duvnjak, L., Lalic, N., Tankova, T. & Bogdanski, P. (2022) Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group. International journal of cardiology, 365, 8-18 doi:10.1016/j.ijcard.2022.07.017.
@article{article, author = {Janez, Andrej and Muzurovic, Emir and Stoian, Anca Pantea and Haluzik, Martin and Guja, Cristian and Czupryniak, Leszek and Duvnjak, Lea and Lalic, Nebojsa and Tankova, Tsvetalina and Bogdanski, Pawel and Papanas, Nikolaos and Nunes, Jos\`{e} Silva and Kempler, Peter and Fras, Zlatko and Rizzo, Manfredi}, year = {2022}, pages = {8-18}, DOI = {10.1016/j.ijcard.2022.07.017}, keywords = {Algorithm, Cardiovascular outcomes trials, GLP-1 receptor agonists, Treatment, Type 2 diabetes mellitus.}, journal = {International journal of cardiology}, doi = {10.1016/j.ijcard.2022.07.017}, volume = {365}, issn = {0167-5273}, title = {Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group}, keyword = {Algorithm, Cardiovascular outcomes trials, GLP-1 receptor agonists, Treatment, Type 2 diabetes mellitus.} }
@article{article, author = {Janez, Andrej and Muzurovic, Emir and Stoian, Anca Pantea and Haluzik, Martin and Guja, Cristian and Czupryniak, Leszek and Duvnjak, Lea and Lalic, Nebojsa and Tankova, Tsvetalina and Bogdanski, Pawel and Papanas, Nikolaos and Nunes, Jos\`{e} Silva and Kempler, Peter and Fras, Zlatko and Rizzo, Manfredi}, year = {2022}, pages = {8-18}, DOI = {10.1016/j.ijcard.2022.07.017}, keywords = {Algorithm, Cardiovascular outcomes trials, GLP-1 receptor agonists, Treatment, Type 2 diabetes mellitus.}, journal = {International journal of cardiology}, doi = {10.1016/j.ijcard.2022.07.017}, volume = {365}, issn = {0167-5273}, title = {Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group}, keyword = {Algorithm, Cardiovascular outcomes trials, GLP-1 receptor agonists, Treatment, Type 2 diabetes mellitus.} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font